Related Experiment Video

Updated: Jul 17, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

The HF epidemic: the need for new treatment strategies

P E Carson1

  • 1Georgetown University, Washington VAMC, Washington, DC, USA. peter.carson@med.va.gov

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|January 3, 2007
PubMed

Insights

Heart failure incidence is rising, especially in the elderly. Future clinical trials should include diverse populations and focus on preserved systolic function, investigating novel therapies like angiotensin II receptor blockers.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure incidence is increasing, particularly in older adults.
  • Current clinical trials may not represent real-world patient demographics, who are often older with multiple co-morbidities.
  • Therapeutic agents must be safe for co-existing conditions.

Purpose of the Study:

  • To review current heart failure therapies and discuss future clinical trial designs.
  • To highlight the need for evaluating novel agents like angiotensin II receptor blockers (ARBs).

Main Methods:

  • Review of current heart failure treatment guidelines and ongoing research.
  • Discussion of limitations in existing clinical trial populations.
  • Emphasis on the role of the renin-angiotensin-aldosterone system (RAAS) inhibitors.

Main Results:

  • Current heart failure management includes ACE inhibitors, beta-blockers, diuretics, spironolactone, and digitalis.
  • Angiotensin II receptor blockers (ARBs) like valsartan are being investigated for improved RAAS inhibition.
  • Existing therapies require careful consideration of patient co-morbidities.

Conclusions:

  • Future heart failure trials should enroll diverse racial groups and the elderly, especially those with preserved systolic function.
  • Large, multicenter studies with internal substudies are needed to explore heart failure mechanisms.
  • Novel therapeutic strategies, including advanced ARBs, warrant further investigation in representative patient populations.

More Related Videos

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...